UnitedHealth under criminal probe for possible Medicare fraud, WSJ reports-March 2024-www.financetom.com

UnitedHealth under criminal probe for possible Medicare fraud, WSJ reports

News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities

UnitedHealth under criminal probe for possible Medicare fraud, WSJ reports

May 26, 2025 8:14 AM

May 14 (Reuters) - The U.S. Justice Department is

investigating UnitedHealth Group ( UNH ) for potential criminal

fraud in its Medicare Advantage business, the Wall Street

Journal reported on Wednesday, citing people familiar with the

matter.

Reuters could not immediately confirm the details of the

report.

(Reporting by Bipasha Dey in Bengaluru; Editing by Arun Koyyur)

Previous page： Stellantis Extends, Amends $13.12 Billion Credit Facility Next page： RBC on Business Jet Market Outlook

Comments

Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.

Show More Comments

Related Articles >

Stellantis Extends, Amends $13.12 Billion Credit Facility

Jul 17, 2024

02:23 PM EDT, 07/17/2024 (MT Newswires) -- Stellantis ( STLA ) said Wednesday it has extended its 12 billion euros ($13.12 billion) syndicated revolving credit facility. The credit facility, originally signed in July 2021, involves 29 banks from Europe, America, and Asia. It is divided into two tranches: 6 billion euros with a three-year term and 6 billion euros with...

RBC on Business Jet Market Outlook

Jul 17, 2024

02:21 PM EDT, 07/17/2024 (MT Newswires) -- RBC's analysis of the business jet market increases its conviction in the long-term demand trends and upside avenues in aftermarket services for leading OEMs. The business jet fleet is the oldest in over two decades, supporting demand for new jets and planned production rate increases. With used inventory levels remaining significantly below the...

4D Molecular Therapeutics Goes Neck To Neck With Rival, Shares New Phase 2 Data For Its Wet AMD Candidate

Jul 17, 2024

Wednesday, 4D Molecular Therapeutics, Inc. ( FDMT )unveiled interim 24-week data from the Population Extension cohort of its PRISM Phase 2 Clinical Trial. The trial evaluates intravitreal 4D-150 in a broad wet AMD patient population. Also Read: Why Is 4D Molecular Therapeutics Stock Trading Lower On Thursday? Genetic Disease-Focused Study Data Released. The findings were presented at the American Society...

-- Altius Renewable Royalties Brief: Reporting Q2 2024 Expected Proportionate Royalty Revenue of US$1.5 million

Jul 17, 2024

02:24 PM EDT, 07/17/2024 (MT Newswires) -- Price: 9.33, Change: -0.08, Percent Change: -0.85 ...